Femasys (NASDAQ:FEMY) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Femasys (NASDAQ:FEMY) from a hold rating to a sell rating in a report released on Saturday morning.

A number of other brokerages also recently commented on FEMY. Lake Street Capital lowered their price target on shares of Femasys to $10.00 and set a “buy” rating for the company in a report on Tuesday, August 18th. Maxim Group reduced their price objective on shares of Femasys to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Finally, Weiss Ratings downgraded shares of Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 17th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $50.00.

Femasys Price Performance

FEMY stock opened at $2.96 on Friday. Femasys has a one year low of $2.02 and a one year high of $22.20. The company’s fifty day moving average price is $3.36 and its 200-day moving average price is $7.00. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.98 and a current ratio of 2.14. The company has a market capitalization of $24.80 million, a PE ratio of -0.84 and a beta of -2.08.

Femasys (NASDAQ:FEMY) last issued its earnings results on Friday, August 14th. The company reported ($1.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.02). The company had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.73 million. Femasys had a negative return on equity of 225.97% and a negative net margin of 534.36%.

Insider Buying and Selling at Femasys

In other news, CFO Dov Elefant bought 15,625 shares of the stock in a transaction on Friday, August 7th. The stock was acquired at an average cost of $3.20 per share, for a total transaction of $50,000.00. Following the acquisition, the chief financial officer owned 15,625 shares of the company’s stock, valued at $50,000. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kathy Lee-Sepsick bought 15,625 shares of the stock in a transaction on Friday, August 7th. The stock was purchased at an average price of $3.20 per share, with a total value of $50,000.00. Following the completion of the acquisition, the chief executive officer directly owned 15,625 shares in the company, valued at approximately $50,000. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 38,750 shares of company stock worth $124,000 over the last 90 days. 7.75% of the stock is currently owned by company insiders.

Institutional Trading of Femasys

Institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp grew its holdings in Femasys by 43.5% during the 4th quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after acquiring an additional 24,500 shares in the last quarter. Kovack Advisors Inc. bought a new stake in shares of Femasys in the 4th quarter valued at about $27,000. Osaic Holdings Inc. bought a new stake in shares of Femasys in the 2nd quarter valued at about $45,000. HRT Financial LP purchased a new stake in shares of Femasys in the 4th quarter worth approximately $30,000. Finally, Cetera Investment Advisers purchased a new stake in shares of Femasys in the 4th quarter worth approximately $36,000. 65.27% of the stock is currently owned by institutional investors.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.